Alder BioPharmaceuticals, Inc. Announces Offering of $200 Million of Convertible Senior Notes Due 2025
BOTHELL, Wash., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a biopharmaceutical company focused on developing novel therapeutic antibodies for the treatment of migraine, announced today an underwritten offering of $200 …